JBIO · IV Rank History
Jade Biosciences, Inc. Common Stock
IV rank shows where JBIO's implied volatility sits within its own recent range: 0 is the lowest reading in the window, 100 the highest. This page gives the 52-week version, the 90-session version our screeners use, the IV percentile, and the daily history.
JBIO's 30-day at-the-money implied volatility was 144.0% as of Oct 21, 2026. Its 52-week IV rank is 78 and its IV percentile is 79%: IV was lower on 79% of the past year's sessions. Over those 52 weeks it ranged from 58.6% (Oct 12, 2026) to 168.0% (Nov 14, 2025). On the 90-session window our screeners use, the IV rank is 91.
JBIO IV rank history
345 sessionsFilled line: 90-session IV rank (0–100, left axis). Dashed line: 30-day at-the-money implied volatility (right axis).
JBIO IV rank and implied volatility as of 2026-10-21
How these are measured. Implied volatility here is JBIO's 30-day at-the-money IV: the implied volatility of the calls and puts struck nearest the share price, blended between the expirations on either side of 30 days so every reading covers the same horizon. It's the IV level options traders usually quote, and it doesn't jump when the nearest expiration rolls from a weekly to a monthly. The 7-day figure is the same measure a week out, so it reacts first to near-term events such as earnings.
52-week IV rank = (today's IV − 52-week low) ÷ (52-week high − 52-week low) × 100. IV percentile is the share of the past year's sessions that closed with lower IV than today. The 90-session IV rank applies the same rank formula to the last 90 sessions, so it reacts faster.
A high reading means JBIO options are expensive relative to their own recent history, which is common ahead of earnings or after a sharp move. It says nothing about which way the stock will go. The Vol Arb Screener ranks every tracked symbol by these measures.
JBIO implied volatility by month
| Month | Avg ATM IV | High | Low | Avg IV Rank (90-session) |
|---|---|---|---|---|
| Oct 2026 (to date) | 97.8% | 152.0% | 58.6% | 43 |
| Sep 2026 | 92.9% | 134.0% | 60.6% | 25 |
| Aug 2026 | 94.7% | 115.9% | 76.2% | 15 |
| Jul 2026 | 101.8% | 113.4% | 91.2% | 15 |
| Jun 2026 | 108.0% | 142.4% | 91.3% | 21 |
| May 2026 | 150.8% | 161.7% | 138.9% | 88 |
| Apr 2026 | 147.4% | 156.9% | 131.4% | 86 |
| Mar 2026 | 131.4% | 155.9% | 98.9% | 66 |
| Feb 2026 | 121.7% | 156.8% | 96.7% | 49 |
| Jan 2026 | 114.0% | 159.4% | 91.2% | 39 |
| Dec 2025 | 106.8% | 140.8% | 67.3% | 34 |
| Nov 2025 | 111.5% | 168.0% | 64.2% | 37 |
| Oct 2025 | 105.7% | 210.5% | 60.0% | 19 |
| Sep 2025 | 90.0% | 150.9% | 52.6% | 6 |
| Aug 2025 | 87.6% | 190.7% | 55.0% | 5 |
| Jul 2025 | 112.3% | 188.0% | 56.3% | 9 |
| Jun 2025 | 93.6% | 182.6% | 57.8% | 15 |
| May 2025 | 230.6% | 687.1% | 86.0% | — |
JBIO IV rank: last 30 sessions
| Date | IV Rank (90-session) | 30-Day ATM IV | 7-Day ATM IV |
|---|---|---|---|
| 2026-10-21 | 91 | 144.0% | — |
| 2026-10-20 | 100 | 152.0% | — |
| 2026-10-19 | 100 | 145.7% | — |
| 2026-10-16 | 55 | 104.6% | — |
| 2026-10-15 | 43 | 94.4% | — |
| 2026-10-14 | 1 | 59.1% | — |
| 2026-10-13 | 42 | 93.4% | 381.9% |
| 2026-10-12 | 0 | 58.6% | 207.0% |
| 2026-10-09 | 72 | 119.7% | — |
| 2026-10-08 | 55 | 105.6% | 211.4% |
| 2026-10-07 | 25 | 83.2% | — |
| 2026-10-06 | 19 | 78.5% | — |
| 2026-10-05 | 22 | 82.9% | — |
| 2026-10-02 | 2 | 62.7% | 75.1% |
| 2026-10-01 | 22 | 82.7% | 95.4% |
| 2026-09-30 | 25 | 85.7% | 81.5% |
| 2026-09-29 | 31 | 91.6% | 92.7% |
| 2026-09-28 | 21 | 82.3% | 71.1% |
| 2026-09-25 | 0 | 60.6% | 60.3% |
| 2026-09-24 | 36 | 103.3% | — |
| 2026-09-23 | 70 | 134.0% | — |
| 2026-09-22 | 52 | 118.0% | — |
| 2026-09-21 | 20 | 89.3% | — |
| 2026-09-18 | 7 | 77.3% | — |
| 2026-09-17 | 21 | 89.5% | — |
| 2026-09-16 | 61 | 126.1% | 492.1% |
| 2026-09-15 | 20 | 89.1% | 226.4% |
| 2026-09-14 | 52 | 117.6% | 186.3% |
| 2026-09-11 | 36 | 103.4% | 148.7% |
| 2026-09-10 | 0 | 70.6% | 82.4% |
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.